• Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years
  • Bioengineered T cells, called CTL019 cells, function as cancer hunters, killing the leukemia cells that normally evade regular T cell surveillance.
  • The personalized cell therapy reprograms a patient’s immune system and offers the potential of long-term success

Share This Article